Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zai Lab Ltd ( (HK:9688) ) has shared an update.
Zai Lab Limited announced an update on the Phase 3 FORTITUDE-101 study, conducted in partnership with Amgen, evaluating bemarituzumab combined with chemotherapy for first-line gastric cancer. While the interim analysis showed significant improvement in overall survival, the final analysis indicated a reduced benefit. The company plans to await results from the FORTITUDE-102 study before proceeding with regulatory filings, with data expected by late 2025 or early 2026.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative medicines. The company is engaged in partnerships and collaborations to advance its pipeline, primarily targeting oncology, autoimmune, and infectious diseases.
Average Trading Volume: 17,115,506
Technical Sentiment Signal: Buy
Current Market Cap: HK$29.09B
See more data about 9688 stock on TipRanks’ Stock Analysis page.